Analysts/Institutional Investor Meet/Con. Call Updates

October 29, 2026 To, To, National Stock Exchange of India Ltd. BSE Limited Exchange Plaza, BKC P.J. Towers, Bandra-Kurla Complex, 25th Floor, Dalal Street, Fort Bandra (East), Mumbai-400 051 Mumbai 400 001 Symbol: JLHL Code: 543980 Subject: Q2 FY27 Earnings Conference Call – Transcript Reference: Intimation of Earnings Conference Call dated October 8, 2026 and Audio Link of Analyst/ Investor Conference Call dated October 26, 2026. Dear Sir/ Madam, Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Q2 FY27 Results Conference Call held on Monday, October 26, 2026 at 10.00 AM (IST) for the quarter and half year ended on September 30, 2026. The same will be available on the website of the Company at www.jupiterhospital.com You are requested to kindly take the aforementioned on record and oblige. Thanking you, For JUPITER LIFE LINE HOSPITALS LIMITED Suma Upparatti Company Secretary & Compliance Officer Encl: As stated above “Jupiter Life Line Hospitals Limited Q2 and H1 FY27 Earnings Conference Call” October 26, 2026 “E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recordings uploaded on the stock exchanges and the Company website on 26th October 2026 will prevail.” MANAGEMENT: DR. ANKIT THAKKER – MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER MR. ANAND APTE – CHIEF BUSINESS AND STRATEGY OFFICER MR. ADITYA GUPTA – SENIOR VICE PRESIDENT CORPORATE AFFAIRS MR. NITIN PATODI – HEAD OF FINANCE MRS. SUMA UPPARATTI – COMPANY SECRETARY AND COMPLIANCE OFFICER SGA – INVESTOR RELATIONS ADVISORS Page 1 of 12 Jupiter Life Line Hospitals Limited October 26, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Jupiter Life Line Hospitals Limited Q2 and H1 FY27 Earnings Conference Call. This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions, and expectations of the company as on the date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. As a reminder, all participants' lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during this conference call, please signal an operator by pressing star, then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Dr. Ankit Thakker, Managing Director and CEO. Thank you, and over to you, sir. Ankit Thakker: Good morning, everyone. I thank you for joining us on our earnings call to discuss the business and financial performance of Q2 and H1 FY27. I hope everyone had a chance to view our financial results and investor presentation, which were posted on our website and the stock exchanges. I am joined this morning by Mr. Anand Apte, our Chief of Business and Strategy; Mr. Aditya Gupta, our Senior VP, Corporate Affairs; Mr. Nitin Patodi our Head of Finance; Ms. Suma Upparatti, our Company Secretary and Compliance Officer; and our investor relations advisors on the call from SGA. I am pleased to share with all of you that following successful negotiations with the landowner, the board has approved the acquisition of the land currently leased for our Pune South hospital. The land measures 11,452 square meters, and the total agreed consideration for the land is INR150 crores. The INR50 crores of deposit that was already paid earlier will be adjusted against this. So, the incremental cash outflow for the company is limited to INR100 crores. The land is expected to be registered in our name in the coming few days. We have always said that we prefer to own the land on which our hospitals are built as it gives us control, certainty, and better long-term financial value. The Pune South project is also progressing well and remains on schedule. At Mira Bhayandar, the project is currently in the regulatory stage, and we expect to commence the next phase of activities before the end of this financial year. BKC is in the planning stage and will soon go into the regulatory clearance process. Coming to our operating hospitals, our existing hospitals continue to perform in line with expectations, with Thane, Pune, and Indore, all staying on course. At Dombivli, the ramp-up is continuing well. The EBITDA impact on the hospital was INR20 lakhs in Q2 compared to INR9.5 crores in Q1. Part of this improvement reflects higher medical admissions during the quarter, driven by a seasonally higher infectious disease burden in this region. This has traditionally been the case with all of our existing hospitals as well, where Q2 occupancy has been higher than Q1 and Q3. The overall ramp-up trajectory of Dombivli, however, remains intact. Page 2 of 12 Jupiter Life Line Hospitals Limited October 26, 2026 Moving to the financial performance, Q2 numbers: the income stood at INR456.5 crores in this quarter. The EBITDA stood at INR106.9 crores in this quarter with a PAT of INR56.4 crores. Half-yearly numbers: the income is INR867.5 crores with an EBITDA of INR186.2 crores and a PAT of INR93.9 crores. The ARPOB is INR71,800. The IP ARPOB is INR58,700. The ALOS is 3.79 days, and the occupancy for first half is 59.5% for all the hospitals, but excluding Dombivli, the occupancy is 64.8%. So, with this, I'm happy to take your questions. Thank you. Moderator: Thank you very much. We will now begin with a question-and-answer session. The first question is from the line of Abin Benny from JM Financial. Please go ahead. Abin Benny: Thank you. Hope I'm audible. First of all, congratulations to the management for a great set of numbers. Sir, my first question, if you could indicatively help us understand what kind of revenues did Dombivli clock in the quarter and the kind of occupancy levels we exited for the hospital? Ankit Thakker: Currently, we have not been giving unit-wise revenue numbers, so I would not have that accessible with me. Abin Benny: Sure, sir. But in terms of metrics, what kind of occupancy levels that we are seeing right now and, given this higher infectious diseases that are there, what kind of metrics or dilution are we seeing right now? Ankit Thakker: Currently, occupancy should be in mid-30s. Abin Benny: 30%, right? For sure, sir. Thank you. And my second question regarding the mature assets, especially Pune and Thane that is there, any brownfield bed expansion opportunities that we might have here, any kind of bed increases that we can see? And second, growth here indicatively, as you have earlier also mentioned, that is much linked to inflation. Apart from that, occupancy-wise, any levers that we can probably see in future? Ankit Thakker: Pune, there is no further scope of expansion. Thane, I have said that we may have possibility to add some beds, subject to regulatory clearance. We have not got the clearance yet, but we remain hopeful to get it soon. If and when that happens, I'll update everybody about that. On Thane front, occupancy is already high, 70%. So, unless the new beds do come in, inflation remains the only lever. Pune, occupancy is close to 70%, so it still has a little more headroom of growth in terms of occupancy as well, besides inflation. Abin Benny: Sure, sir. Thank you. I will join back the queue. Ankit Thakker: Thank you. Moderator: Thank you. The next question is from the line of Kalkesh Jain from Jain Securities. Please go ahead. Kalkesh Jain: Yes, hi. Thanks for the opportunity. So, one question I have. So, Dombivli EBITDA loss narrowed sharply from INR9.4 crores or INR9.5 crores in Q1 to INR0.2 crores in Q2 partly due Page 3 of 12 Jupiter Life Line Hospitals Limited October 26, 2026 to the higher infectious disease admissions. What could be the Q2 losses have been excluding this seasonal benefit? And what loss should we expect in Q3 as admissions decline? Ankit Thakker: [Showing first 8,000 characters — download PDF for full document]